# Westlake Chemical Partners LP: overview

WLKP · NYSE · CIK 1604665 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/wlkp.md) · [Financials](/companies/wlkp/financials.md) · [Filings](/companies/wlkp/filings.md) · [Insiders](/companies/wlkp/insiders.md)

Latest reported revenue: [$297.1m](/filings/0001604665-26-000027.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:Revenues, accession 0001604665-26-000027).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [277](/filings/0001604665-25-000042.md) | [290 d](/filings/0001604665-26-000010.md) | [238](/filings/0001604665-26-000017.md) | [297](/filings/0001604665-26-000027.md) | [309](/filings/0001604665-25-000042.md) | [323 d](/filings/0001604665-26-000010.md) | [306](/filings/0001604665-26-000017.md) | [297](/filings/0001604665-26-000027.md) |
| Gross margin | % | [42.2%](/filings/0001604665-25-000042.md) | [34.0% d](/filings/0001604665-26-000010.md) | [22.8%](/filings/0001604665-26-000017.md) | [32.8%](/filings/0001604665-26-000027.md) | [32.2%](/filings/0001604665-25-000042.md) | [30.0% d](/filings/0001604665-26-000010.md) | [30.7%](/filings/0001604665-26-000017.md) | [31.9%](/filings/0001604665-26-000027.md) |
| Operating margin | % | [39.6%](/filings/0001604665-25-000042.md) | [31.7% d](/filings/0001604665-26-000010.md) | [19.6%](/filings/0001604665-26-000017.md) | [30.7%](/filings/0001604665-26-000027.md) | [29.8%](/filings/0001604665-25-000042.md) | [27.8% d](/filings/0001604665-26-000010.md) | [28.3%](/filings/0001604665-26-000017.md) | [29.4%](/filings/0001604665-26-000027.md) |
| Net margin | % | [6.5%](/filings/0001604665-25-000042.md) | [5.2% d](/filings/0001604665-26-000010.md) | [2.1%](/filings/0001604665-26-000017.md) | [4.9%](/filings/0001604665-26-000027.md) | [4.7%](/filings/0001604665-25-000042.md) | [4.5% d](/filings/0001604665-26-000010.md) | [4.6%](/filings/0001604665-26-000017.md) | [4.8%](/filings/0001604665-26-000027.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [111 d](/filings/0001604665-25-000042.md) | [119 d](/filings/0001604665-26-000010.md) | [29.8](/filings/0001604665-26-000017.md) | [(15.3) d](/filings/0001604665-26-000027.md) | [75.6 d](/filings/0001604665-25-000042.md) | [112 d](/filings/0001604665-26-000010.md) | [105](/filings/0001604665-26-000017.md) | [117 d](/filings/0001604665-26-000027.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [188](/filings/0001604665-23-000009.md) | [250](/filings/0001604665-23-000009.md) | [1,191](/filings/0001604665-26-000010.md) | [1,136](/filings/0001604665-26-000010.md) | [1,167](/filings/0001604665-26-000010.md) |
| Gross margin | % | [234.6%](/filings/0001604665-24-000010.md) | [150.8%](/filings/0001604665-25-000011.md) | [32.5%](/filings/0001604665-26-000010.md) | [36.9%](/filings/0001604665-26-000010.md) | [29.8%](/filings/0001604665-26-000010.md) |
| Operating margin | % | [218.1%](/filings/0001604665-24-000010.md) | [138.9%](/filings/0001604665-25-000011.md) | [30.0%](/filings/0001604665-26-000010.md) | [34.4%](/filings/0001604665-26-000010.md) | [27.4%](/filings/0001604665-26-000010.md) |
| Net margin | % | [43.8%](/filings/0001604665-24-000010.md) | [25.6%](/filings/0001604665-25-000011.md) | [4.6%](/filings/0001604665-26-000010.md) | [5.5%](/filings/0001604665-26-000010.md) | [4.2%](/filings/0001604665-26-000010.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [327](/filings/0001604665-24-000010.md) | [410](/filings/0001604665-25-000011.md) | [405](/filings/0001604665-26-000010.md) | [436](/filings/0001604665-26-000010.md) | [202](/filings/0001604665-26-000010.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/wlkp/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $110.7m | 4,972,812 |  | Unchanged |
| [Energy Income Partners, LLC](/funds/1388814.md) | 2026-06-30 | $35.4m | 1,589,566 |  | Added +7,559 |
| [MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.](/funds/1705339.md) | 2026-06-30 | $16.0m | 719,852 |  | Added +28,057 |
| [Clearbridge Investments, LLC](/funds/1348883.md) | 2026-06-30 | $14.1m | 633,569 |  | Unchanged |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $9.8m | 442,165 |  | Reduced −15,562 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $5.3m | 238,363 |  | Added +18,705 |
| [CITIGROUP INC](/funds/831001.md) | 2026-06-30 | $4.9m | 218,105 |  | Reduced −10,650 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $3.9m | 174,309 |  | Reduced −53,843 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $3.8m | 170,333 |  | Reduced −10,238 |
| [Pathway Financial Advisers, LLC](/funds/2024152.md) | 2026-06-30 | $2.4m | 107,894 |  | Added +1,296 |

## Recent filings

[All 409 filings](/companies/wlkp/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-31 | 17:03 ET | [8-K](/filings/0001193125-26-377003.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-377003 |
| 2026-08-05 | 14:27 ET | [10-Q](/filings/0001604665-26-000027.md) | Quarterly report, period 2026-06-30 | 0001604665-26-000027 |
| 2026-08-04 | 07:27 ET | [8-K](/filings/0001604665-26-000022.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001604665-26-000022 |
| 2026-05-06 | 13:49 ET | [10-Q](/filings/0001604665-26-000017.md) | Quarterly report, period 2026-03-31 | 0001604665-26-000017 |
| 2026-05-05 | 07:30 ET | [8-K](/filings/0001604665-26-000013.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001604665-26-000013 |
| 2026-04-20 | 17:08 ET | [8-K](/filings/0001193125-26-164239.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-164239 |
| 2026-03-04 | 13:01 ET | [10-K](/filings/0001604665-26-000010.md) | Annual report, period 2025-12-31 | 0001604665-26-000010 |
| 2026-02-24 | 07:22 ET | [8-K](/filings/0001604665-26-000003.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001604665-26-000003 |
| 2026-02-23 | 16:56 ET | [8-K](/filings/0001193125-26-064229.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-064229 |
| 2025-10-31 | 15:02 ET | [10-Q](/filings/0001604665-25-000042.md) | Quarterly report, period 2025-09-30 | 0001604665-25-000042 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001604665-26-000010.md), filed Mar 4, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/257e6965-eb87-44f2-8c7d-4748af6b21db)

## About the filer

- CIK: 1604665
- Tickers: WLKP
- Exchange: NYSE
- SIC code: 2860 Industrial Organic Chemicals
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.